CA2982442A1 - Compositions and methods for treating intestinal hyperpermeability - Google Patents

Compositions and methods for treating intestinal hyperpermeability Download PDF

Info

Publication number
CA2982442A1
CA2982442A1 CA2982442A CA2982442A CA2982442A1 CA 2982442 A1 CA2982442 A1 CA 2982442A1 CA 2982442 A CA2982442 A CA 2982442A CA 2982442 A CA2982442 A CA 2982442A CA 2982442 A1 CA2982442 A1 CA 2982442A1
Authority
CA
Canada
Prior art keywords
tyrosine
methyl
alpha
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2982442A
Other languages
English (en)
French (fr)
Inventor
Steven Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/686,545 external-priority patent/US9308188B2/en
Priority claimed from US15/059,602 external-priority patent/US9763903B2/en
Application filed by Individual filed Critical Individual
Publication of CA2982442A1 publication Critical patent/CA2982442A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA2982442A 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability Abandoned CA2982442A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/686,545 US9308188B2 (en) 2013-10-22 2015-04-14 Compositions and methods for treating intestinal hyperpermeability
US14/686,545 2015-04-14
US15/059,602 US9763903B2 (en) 2013-10-22 2016-03-03 Compositions and methods for treating intestinal hyperpermeability
US15/059,602 2016-03-03
PCT/US2016/024432 WO2016167944A2 (en) 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability

Publications (1)

Publication Number Publication Date
CA2982442A1 true CA2982442A1 (en) 2016-10-20

Family

ID=57126753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982442A Abandoned CA2982442A1 (en) 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability

Country Status (12)

Country Link
EP (2) EP3283115B1 (https=)
JP (1) JP6858131B2 (https=)
KR (1) KR20180015126A (https=)
CN (1) CN107835695B (https=)
AU (1) AU2016247301A1 (https=)
BR (1) BR112017022184A2 (https=)
CA (1) CA2982442A1 (https=)
EA (1) EA038339B1 (https=)
IL (1) IL254963A0 (https=)
MX (1) MX2017013176A (https=)
PH (1) PH12017501864A1 (https=)
WO (1) WO2016167944A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
WO2020018291A1 (en) * 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
EP3823593A4 (en) * 2018-07-19 2022-04-20 Yamo Pharmaceuticals LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM
KR102726917B1 (ko) 2019-02-01 2024-11-07 닥터레이몬드 랩(주) 자폐증의 예측방법
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
AU2001251595A1 (en) * 2000-04-13 2001-10-30 William T Evans Gaba substrate and the use thereof for treating cognitive and emotional disorders
CA2582346A1 (en) * 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
WO2012123819A1 (en) * 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
PL220308B1 (pl) * 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
JP6796372B2 (ja) * 2012-01-03 2020-12-09 キュアマーク， リミテッド ライアビリティ カンパニー 神経障害および精神障害の行動症状を治療する方法
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US9326962B2 (en) * 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability

Also Published As

Publication number Publication date
EP3283115C0 (en) 2024-06-12
WO2016167944A8 (en) 2017-11-02
JP2018511639A (ja) 2018-04-26
KR20180015126A (ko) 2018-02-12
EP4438059A2 (en) 2024-10-02
EP4438059A3 (en) 2025-01-01
IL254963A0 (en) 2017-12-31
EA201792278A1 (ru) 2018-04-30
PH12017501864A1 (en) 2018-03-05
WO2016167944A3 (en) 2017-08-10
WO2016167944A2 (en) 2016-10-20
JP6858131B2 (ja) 2021-04-14
CN107835695A (zh) 2018-03-23
AU2016247301A1 (en) 2017-10-26
EP3283115A2 (en) 2018-02-21
BR112017022184A2 (pt) 2018-07-03
CN107835695B (zh) 2021-07-09
MX2017013176A (es) 2018-01-30
EA038339B1 (ru) 2021-08-11
EP3283115B1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
US9763903B2 (en) Compositions and methods for treating intestinal hyperpermeability
AU2020203101B9 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US9308188B2 (en) Compositions and methods for treating intestinal hyperpermeability
EP3283115B1 (en) Compositions for treating autism
US12453709B2 (en) Compositions and methods for treating autism
US10751313B2 (en) Compositions and methods for treating autism
JP2021530569A (ja) 自閉症を処置するための組成物および方法
JP2021530568A (ja) 自閉症を処置するための組成物および方法
HK40116464A (en) Compositions and methods for treating intestinal hyperpermeability

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220621